Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in the Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis.

Purpose: The optimal dosing strategy for direct oral anticoagulants (DOACs) in extended treatment of venous thromboembolism (VTE) remains debated, particularly in balancing efficacy and bleeding risk.

Methods: A systematic review and meta-analysis was performed to compare reduced-dose versus full-dose DOACs for extended VTE treatment. Databases including PubMed, Embase, and Cochrane Library were searched from inception to March 2025 for randomized controlled trials (RCTs) involving adult patients treated with different DOAC doses for VTE.

Mortality Trends of Co-occurring Cirrhosis and Hepatocellular Carcinoma in the USA, 1999-2022: A Nationally Representative Sample.

Objective: Cirrhosis, caused by chronic liver diseases, leads to impaired liver function and increases the risk of hepatocellular carcinoma (HCC). This study analyzed CDC WONDER data to examine US patients where both cirrhosis and HCC were listed as co-occurring causes of death.

Methods: Mortality records (1999-2022) were queried for deaths where both HCC (ICD-10 = C22.

Importance of extracorporeal membrane oxygenation (ECMO) in congenital heart diseases: a systematic review.

Background: Congenital heart diseases (CHDs) represent a significant healthcare challenge with incidence rates of 17.9 per 1000 live births. Extracorporeal membrane oxygenation (ECMO) has become an invaluable therapeutic option providing essential aid to support both cardiac as well as pulmonary failure.

Where Do Patients With Cirrhosis Die? A CDC WONDER Analysis From 1999 to 2020.

Background: Liver Cirrhosis is a growing cause of morbidity and mortality worldwide, but significant knowledge gaps remain regarding disparities in the place of patient death. This study aims to analyze the place of death trends for cirrhosis patients in the United States from 1999 to 2020, to direct preventive and palliative care measures.

Methods: In this descriptive study, death certificates were examined using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database, using ICD codes K70.

Concomitant mortality trends due to obesity and hypertension in the U.S.: a 20-year retrospective analysis of the CDC WONDER database.

Background: Hypertension (HTN) and obesity are leading, interrelated risk factors for cardiovascular disease, stroke, and kidney disease in the United States. Despite advances in medical therapies and public health interventions, the joint mortality burden associated with these conditions remains substantial. We sought to characterize national trends and demographic disparities in obesity- and hypertension-related mortality from 2000 to 2019 using the CDC WONDER database.

Evaluating Wharton's jelly-derived stem cell therapy in autism: Insights from a case study.

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder affecting over 2% of the global population, marked by social communication deficits and repetitive behaviors. Kabatas explored the efficacy and safety of Wharton's jelly-derived mesenchymal stem cell (WJ-MSC) therapy in a 4-year-old child with ASD. Using the childhood autism rating scale and Denver II developmental screening test, significant improvements were seen after six WJ-MSC sessions, with no adverse events over 2 years.

Intravascular Imaging-Guided Versus Angiography-Guided Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Despite the potential benefits, intravascular imaging for guiding percutaneous coronary intervention (PCI) remains underutilized. Recent trials have provided new data, prompting a need for updated insights. This study aimed to perform a comprehensive meta-analysis to compare the clinical outcomes of intravascular imaging-guided PCI versus angiography-guided PCI, thereby evaluating the relative effectiveness of these two guidance strategies in improving patient outcomes.

Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta‑analysis.

Background: Myasthenia gravis (MG) is a chronic, complex autoimmune disorder characterized by the production of autoantibodies that destroy neuromuscular junctions. Blocking the neonatal Fc receptors (FcRn) enhances IgG catabolism, offering a novel therapeutic approach.

Methods: PubMed, Embase, and the Cochrane Library were searched up to February 2025, for RCTs evaluating FcRn inhibitors in MG.

Temporal trends in heart failure and acute kidney injury-related mortality in the U.S.: a 21-year retrospective analysis of the CDC WONDER database.

Background: Heart failure (HF) and acute kidney injury (AKI) are leading contributors to morbidity and mortality in the United States, often coexisting as part of the cardiorenal syndrome. Understanding long-term mortality trends is crucial for guiding healthcare policies and interventions. This study analyses national trends in HF- and AKI-related mortality from 1999 to 2020, with a focus on age-adjusted mortality rates (AAMR) and disparities across gender, race/ethnicity, urbanization, and geographic regions.

Trends and Disparities in Acute Myocardial Infarction and Type 2 Diabetes Mellitus-Related Mortality in the United States from 1999-2022.

Background And Aims: Acute myocardial infarction (AMI) and type 2 diabetes mellitus (T2DM) are leading causes of mortality, with significant demographic and regional disparities. This study examined mortality trends related to AMI and T2DM among U.S.

Trends in mortality due to ischemic heart diseases among patients with Alzheimer's disease in the United States from 1999 to 2020.

Background: Ischemic heart diseases (IHD) and Alzheimer's Disease (AD) significantly contribute to mortality in aging population. Understanding mortality trends where these conditions overlap is crucial for developing targeted interventions for vulnerable populations.

Methods: We analyzed CDC WONDER mortality data from 1999 to 2020 for individuals aged ≥45 years.

Mortality patterns of coronary artery diseases and atrial fibrillation in adults in the United States from 1999 to 2022: An analysis using CDC WONDER.

Background: Coronary artery disease (CAD) and atrial fibrillation (AF) contribute significantly to global mortality and frequently co-exist due to shared risk factors like hypertension and diabetes. This study seeks to explore the relatively overlooked area of mortality patterns among adults who have both coronary artery disease and atrial fibrillation.

Methods: Mortality data for individuals aged ≥25 were obtained from CDC WONDER using ICD-10 codes I20-25 (CAD) and I48 (AF).

Trends in atherosclerotic heart disease-related mortality among U.S. adults aged 35 and older: A 22-year analysis.

Background: Atherosclerotic heart disease (ASHD) remains a leading cause of mortality worldwide, especially among older adults. Understanding the long-term mortality trends in ASHD can guide public health strategies and address demographic disparities.

Methods: Mortality data for individuals aged 35 years and older were extracted from the CDC WONDER database.

Trends in Mortality Due to Cardiovascular Diseases Among Patients With Parkinson's Disease in the United States: A Retrospective Analysis.

Background: Parkinson disease (PD) and cardiovascular diseases (CVD) present significant health burdens, particularly among older adults. Patients with PD have an elevated risk of CVD-related mortality. Analyzing mortality trends in this population may help guide focused interventions.

Letter to Editor Regarding "Use of Artificial Intelligence Software to Detect Intracranial Aneurysms: A Comprehensive Stroke Center Experience".

Artificial intelligence (AI) is increasingly significant in neurosurgery, enhancing differential diagnosis, preoperative evaluation, and surgical precision. A recent study in World Neurosurgery evaluated AI's role in aneurysm detection, comparing conventional computed tomography angiography images with AI analysis. AI identified 33 potential aneurysms, with 16 confirmed by radiologists, demonstrating a sensitivity of 36%, specificity of 97.

Advancing aneurysm management: the potential of AI and machine learning in enhancing safety and predictive accuracy.

Cerebral aneurysm rupture, the predominant cause of non-traumatic subarachnoid hemorrhage, underscores the need for effective treatment and early detection methods. A study in Neurosurgical Review compared microsurgical clipping to endovascular therapy in 130 patients with middle cerebral artery (MCA) aneurysms, finding significantly fewer serious adverse events (SAEs) and neurological complications in the endovascular group. This suggests endovascular therapy's superiority in safety and reducing complications for MCA aneurysm patients.

Revolutionizing Aneurysm detection: The role of artificial intelligence in reducing rupture rates.

Cerebral aneurysms, affecting 2-5% of the global population, are often asymptomatic and commonly located within the Circle of Willis. A recent study in Neurosurgical Review highlights a significant reduction in the annual rupture rates of unruptured cerebral aneurysms (UCAs) in Japan from 2003 to 2018. By analyzing age-adjusted mortality rates of subarachnoid hemorrhage (SAH) and the number of treated ruptured cerebral aneurysms (RCAs), researchers found a substantial decrease in rupture rates-from 1.